New York State Common Retirement Fund reduced its stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB) by 0.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,400 shares of the biotechnology company’s stock after selling 1 shares during the quarter. New York State Common Retirement Fund owned 0.08% of Pacific Biosciences of California worth $265,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of PACB. TIAA CREF Investment Management LLC increased its stake in Pacific Biosciences of California by 4.3% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 219,861 shares of the biotechnology company’s stock valued at $783,000 after buying an additional 9,062 shares during the last quarter. Teachers Advisors LLC increased its stake in Pacific Biosciences of California by 0.8% in the 2nd quarter. Teachers Advisors LLC now owns 991,284 shares of the biotechnology company’s stock valued at $3,529,000 after buying an additional 7,574 shares during the last quarter. Stephens Inc. AR increased its stake in Pacific Biosciences of California by 2.3% in the 2nd quarter. Stephens Inc. AR now owns 284,991 shares of the biotechnology company’s stock valued at $1,015,000 after buying an additional 6,274 shares during the last quarter. Alliancebernstein L.P. increased its stake in Pacific Biosciences of California by 45.5% in the 2nd quarter. Alliancebernstein L.P. now owns 114,200 shares of the biotechnology company’s stock valued at $407,000 after buying an additional 35,700 shares during the last quarter. Finally, Kennedy Capital Management Inc. increased its stake in Pacific Biosciences of California by 52.4% in the 2nd quarter. Kennedy Capital Management Inc. now owns 1,240,391 shares of the biotechnology company’s stock valued at $4,416,000 after buying an additional 426,269 shares during the last quarter. 65.22% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/11/21/new-york-state-common-retirement-fund-cuts-position-in-pacific-biosciences-of-california-inc-pacb.html.

Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) opened at $3.06 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.75 and a quick ratio of 3.15. Pacific Biosciences of California, Inc. has a 52 week low of $2.66 and a 52 week high of $8.00.

Pacific Biosciences of California (NASDAQ:PACB) last released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.01. The company had revenue of $23.54 million for the quarter, compared to analyst estimates of $28.29 million. Pacific Biosciences of California had a negative net margin of 95.97% and a negative return on equity of 97.50%. Pacific Biosciences of California’s revenue for the quarter was down 6.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.19) EPS. analysts forecast that Pacific Biosciences of California, Inc. will post -0.88 EPS for the current year.

Several equities research analysts have issued reports on the stock. CL King lowered shares of Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $6.80 price target on the stock. in a research note on Thursday, September 28th. BidaskClub upgraded shares of Pacific Biosciences of California from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 8th. First Analysis lowered shares of Pacific Biosciences of California from an “overweight” rating to an “equal weight” rating and set a $4.00 price target on the stock. in a research note on Friday, November 3rd. Finally, Zacks Investment Research lowered shares of Pacific Biosciences of California from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $6.27.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.

Institutional Ownership by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Stock Ratings for Pacific Biosciences of California Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California Inc. and related stocks with our FREE daily email newsletter.